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Abstract
Reduced cardiac mortality and morbidity have long been observed in association with omega-3 long chain
polyunsaturated fatty acids (LC-PUFA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)
from fish consumption, without clear physiological explanation. This review seeks to identify mechanisms of
action based on evidence: of physiological effects, active components and effective intakes. Fish oil pleiotropic
effects reveal actions that are either intrinsic: effects on cardiac function dependent upon membrane
incorporation; or extrinsic: indirect cardiac effects through vascular disease. Extrinsic actions require EPA +
DHA doses >3 g/day. Intrinsic effects derive from usual dietary intakes, /day and include improved
myocardial oxygen efficiency, heart rate, nutritional preconditioning against ischaemic injury, arrhythmias and
heart failure. Myocardial Na+ and K+ currents are non-selectively modulated by omega-3 and omega-6 PUFA
to stabilise cells in vitro, but not by fish oil-induced membrane change. In contrast, cellular Ca2+ overload
involved in ischaemic injury, arrhythmia and spontaneous pacemaker activity are modulated by both dietary
fish oil and in vitro omega-3 LC-PUFA. A potential linking role of bioactive epoxy and hydroxy PUFA
derivatives requires investigation. Omega-3 DHA predominates over EPA in population intake, is
preferentially incorporated into myocardium and is selectively active in heart rate and arrhythmia modulation,
but EPA predominates in clinical trials. Myocardial selectivity for DHA and independent intrinsic and
extrinsic physiological mechanisms underpinning diverse clinical endpoints can explain some contradictory
outcomes of clinical trials. Intrinsic modulation of intracellular Ca2+ handling provides a unifying
physiologically plausible basis for intrinsic fish oil actions and insight to nutritional optimisation of cardiac
function.
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Reduced cardiac mortality and morbidity have long been observed in association with omega-
3 long chain polyunsaturated fatty acids (LC-PUFA), eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA) from fish consumption, without clear physiological 
explanation. This review seeks to identify mechanisms of action, based on evidence of 
physiological effects, active components and effective intakes.   
 
Fish oil pleiotropic effects reveal actions that are either intrinsic: effects on cardiac function 
dependent upon membrane incorporation; or extrinsic: indirect cardiac effects through 
vascular disease. Extrinsic actions require EPA+DHA doses >3g.d-1. Intrinsic effects derive 
from usual dietary intakes, <1g.d-1 and include improved myocardial oxygen-efficiency, heart 
rate, nutritional preconditioning against ischaemic injury, arrhythmias and heart failure.  
Myocardial Na+ and K+ currents are non-selectively modulated by omega-3 and omega-6 
PUFA to stabilise cells in vitro, but not by fish oil-induced membrane change. In contrast, 
cellular Ca2+ overload involved in ischaemic injury, arrhythmia and spontaneous pacemaker 
activity are modulated by both dietary fish oil and in vitro omega-3 LC-PUFA. A potential 
linking role of bioactive epoxy and hydroxy PUFA derivatives requires investigation. 
Omega-3 DHA predominates over EPA in population intake, is preferentially incorporated 
into myocardium and is selectively active in heart rate and arrhythmia modulation, but EPA 
predominates in clinical trials. 
 
Myocardial selectivity for DHA and independent intrinsic and extrinsic physiological 
mechanisms underpinning diverse clinical endpoints can explain some contradictory 
outcomes of clinical trials. Intrinsic modulation of intracellular Ca2+ handling provides a 
unifying physiologically plausible basis for intrinsic fish oil actions and insight to nutritional 
optimisation of cardiac function.   
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[Ca2+]i  intracellular Ca
2+ concentration 
AA  arachidonic acid 
ALA  alpha-linolenic acid 
DHA  docosahexaenoic acid 
DPA   docosapentaenoic acid 
EET  epoxyeicosatrienoic acids  
EPA  eicosapentaenoic acid 
ETYA  eicosatetraynoic acid 
GISSI  Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico 
HDoHE  hydroxydocosahexaenoic acids 
HETE  hydroxyeicosatetraenoic acids 
HRV   heart rate variability 
If  funny current 
IP3  inositol trisphosphate 
ITO  transient outward current 
LA  linoleic acid 
LC   long-chain 




Epidemiological studies consistently demonstrate cardiovascular health benefits of including 
fish in the diet, first revealed as a low rate of ischaemic heart disease in Greenland Inuit 
(Bang and Dyerberg 1972, 1980). Evidence from many subsequent observational studies 
supports a role for omega-3 polyunsaturated fatty acids (PUFA) contained in fish, not only in 
clinical prevention of heart disease death, but in promoting heart health.  The earliest of these 
was a prospective cohort study in the Netherlands, which commenced in 1960 with 872 
healthy men aged 40-59 y and after 20 y follow-up reported that men who ate fish were 50% 
less likely to die prematurely from coronary heart disease (Kromhout et al. 1985).   The 
Physicians Health Study, of over 20,000 men initially free of heart disease, also showed that 
regular fish consumption was associated markedly reduced cardiovascular mortality over 11 
years (Albert et al. 1998) and a 30% lower risk of developing heart failure over 30 years 
(Wilk et al. 2012).  A review of the evidence presented as the recommendation of the 
American Heart Association in 2002, concluded that risk of coronary heart disease morbidity 
and mortality is reduced in persons regularly consuming omega-3 PUFA, especially the long 
chain PUFA (LC-PUFA) eicosapentaenoic acid (EPA; 20:5 n-3) and docosahexaenoic acid 
(DHA; 22:6 n-3) derived from fish or fish oil (Kris-Etherton et al. 2002).   
 
The overall conclusion endorsing fish oil fatty acids was based on epidemiological and 
clinical trials data gathered over several decades, stimulated by the seminal observations in 
the 1970s of low cardiovascular disease incidence in Greenland Inuit (Dyerberg et al. 1978). 
However, not all studies have been confirmatory and debate surrounds the role of omega-3 
PUFA in cardiac physiology, cardiovascular health and disease prevention.  While numerous 
meta-analyses of clinical research data support this conclusion (Bucher et al. 2002; Hooper et 
al. 2004; Mozaffarian et al. 2005b; Zhao et al. 2009; Mozaffarian and Wu 2011; Musa-
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Veloso et al. 2011; Casula et al. 2013), others do not (Hooper et al. 2006; Hooper et al. 2009; 
Khoueiry et al. 2013), creating controversy and argument.   
 
Some clues to the both origins and a solution to the debate come from early observations 
reporting physiological effects of fish oil on the heart to prevent ventricular fibrillation or 
sustained arrhythmias during ischaemia and reperfusion in rats (McLennan et al. 1988), 
subsequently confirmed in many animal studies (Matthan et al. 2005; McLennan and 
Abeywardena 2005). This stimulated applied clinical interest, and a case control study of 
sudden arrhythmic death victims revealed that regular fish consumption was associated with 
reduced risk of fatal cardiac events, by virtue of the omega-3 LC-PUFA in the fish (Siscovick 
et al. 1995).  Reviews and health authority reports cite a disparate range of potential 
mechanisms of action (Schmidt et al. 2000; Kris-Etherton et al. 2002; Schmidt et al. 2005; 
Colquhoun et al. 2008; Mozaffarian and Wu 2011; Baum et al. 2012).  It is the premise of 
this review that much of the controversy surrounding omega-3 cardioprotection can be 
attributed to an inadequate understanding of the role of these fatty acids in cardiac 
physiology, which has resulted in clinical trials that are based on ill-defined or poorly 
constructed hypotheses and with inappropriate pooling of disparate population groups.  For 
example, a clinical trial that found no effect of omega-3 LC-PUFA in reducing the risk of the 
“first major cardiovascular event”, recruited equally from high risk myocardial infarction and 
stroke victims (Galan et al. 2011). It combined as the primary endpoint: fatal or non-fatal 
myocardial infarction; sudden arrhythmic death; fatal or nonfatal stroke; aortic dissection; 
and heart failure.  The primary endpoint therefore considered a variety of disparate 
physiological mechanisms of action of omega-3 PUFA, such as prevention of arrhythmia, 
thrombosis, atherosclerosis, infarction, hypertension, vascular medial damage and heart 
failure as being equally valid.  A stroke victim is not necessarily at risk of heart failure or 
myocardial infarction.   
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The failure of some clinical intervention studies to fulfil the promise of the epidemiology 
may also emanate from the common use of fish oil supplements in clinical trials that do not 
represent the omega-3 fatty acids consumed in fish.  Again, this discrepancy is based on 
incomplete understanding of the mechanisms of action of fish oil fatty acids and imprecise 
recognition of the active component(s).  With little understood about the underlying 
mechanisms of n-3 PUFA effects on cardiac function and dysfunction, there is “ambivalence 
to adoption and incorporation into guidelines” (Tang and Samara 2011).  A widespread  
misalignment of hypotheses with known mechanisms of action will be explained through the 
evidence for an intrinsic role of fish oil fatty acids in cardiac physiology, then integrated with 
the evidence for and against individual cellular and ionic mechanisms to develop a unifying 
hypothesis. 
1.1. Omega-3 polyunsaturated fatty acids 
Polyunsaturated fatty acids cannot be formed de novo in mammals and must be obtained 
from the diet.  The principal omega-6 PUFA found incorporated into cardiac membranes are 
linoleic acid (18:2 n-6) and arachidonic acid (AA, 20:4 n-6) (numbering derived from 20 
carbon chain with 4 double bonds, with the first at the 6th carbon from the methyl terminal of 
the molecule). Intake of omega-6 fatty acids is widespread in western diets, with  linoleic 
acid readily obtained from plants, especially grains and seed oils (Harris et al. 2009b).  Whilst 
some arachidonic acid is obtained from meat, most is formed from linoleic acid, which is 
readily converted to arachidonic acid in the body and there is no inter-conversion of omega-6 
to omega-3 PUFA families (Sprecher 2000) (Figure 1).  Some dietary plant sources such as 
linseed (flax), canola and soy contain the omega-3 PUFA α-linolenic acid (ALA, 18:3 n-3), 
however substrate competition between omega-3 PUFA and omega-6 PUFA occurs at all 
steps in the pathway of elongation and desaturation (Figure 1), especially at the rate limiting 
 7
-6 desaturase enzyme.  With this competition, together with the preponderance of omega-6 
PUFA in the western diet, formation of DHA from its plant precursor is extremely poor 
(Sprecher 2000; Burdge and Calder 2005).  Moreover, the -6 desaturase enzyme is involved 
at two points in the pathway and as ALA increases from an optimal concentration, the total 
dietary PUFA concentration (omega-3 plus omega-6) becomes inhibitory to the production of 
DHA (Figure 1) (Gibson et al. 2013).  As a consequence, DHA concentrations in human 
tissues actually decline with high dietary intakes of ALA (Burdge and Calder 2005). 
Therefore the tissue concentrations of EPA and especially DHA can be best elevated by 
direct dietary intake of fish or fish oils containing the preformed omega-3 PUFA (Metcalf et 
al. 2007; Harris et al. 2009a; Slee et al. 2010).  It has been suggested that dietary linoleic acid 
intake should be reduced to restore the balance (Simopoulos 2006), whilst others argue that 
omega-6 PUFA and omega-3 PUFA are equally vital to human health (Harris 2010). A 
debate about the importance of dietary balance of omega-3/omega-6 PUFA has established 
that the ratio, whilst important in determining the fate of dietary ALA (Harris 2006; Gibson et 
al. 2013) has no influence on membrane incorporation when omega-3 fatty acids are 
consumed as the LC-PUFA EPA or DHA (Griffin 2008; Slee et al. 2010) and also has no 
influence on the clinical efficacy of fish oil fatty acids (Mozaffarian et al. 2005a; Harris et al. 
2009b).  This debate has been further clouded by failure to be explicit about which of the 
omega-3 PUFA have been investigated (Abbott et al. 2012).  Therefore, for the present 
review, the term LC-PUFA is used to define only those fatty acids of 20 carbons or longer 
(e.g. fish oil fatty acids EPA and DHA, not ALA). 
[Figure 1. near here] 
Early observations of high bleeding tendency in Greenland Inuit associated with the change 
in balance of enzymic production of the pro-aggregation vasoconstrictor eicosanoid 
thromboxane and anti-aggregatory vasodilator eicosanoid, prostacyclin from EPA in platelets 
and endothelium (Dyerberg et al. 1978), together with demonstration of triacylglycerol 
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lowering in clinical settings (Connor et al. 1993) and blood pressure lowering or 
antihypertensive actions (Morris et al. 1993), alluded to several potential physiological roles 
for the omega-3 fatty acids.  However, it is now recognised that high daily intakes are 
necessary to inhibit haemostasis and thrombosis or reduce triacylglycerols or blood pressure 
in human studies (Morris et al. 1993; Nordoy et al. 2001; Cabo et al. 2012; Wachira et al. 
2014). (Daily intakes of 6 g omega-3 LC-PUFA as fish oil had no significant effect on post-
surgical bleeding after coronary artery bypass graft or valve surgery (Metcalf et al. 2007); 
fish oil and concentrates of >3 g.d-1 omega-3 LC-PUFA are used therapeutically to lower 
plasma triacylglycerols effectively (Skulas-Ray et al. 2011); small reductions in BP ranging 
from 1 mmHg to 6 mmHg are achieved with daily 2-4 g of omega-3 LC-PUFA, and 
clinically-relevant BP changes require more than 3 g.d-1 of omega-3 LC-PUFA from fish or 
fish oil (Cabo et al. 2012)).  Contrast these high intakes with those associated with the 
reduced risk of sudden cardiac death (regular intake of fish equivalent to omega-3 LC-PUFA 
intake of 100 mg.d-1 is associated with 30% reduction of risk and 185 mg.d-1 is associated 
with 50% reduction in risk (Siscovick et al. 1995)), or prevention of heart disease deaths 
(15% reduction in mortality with each 100 mg.d-1 intake of omega-3 LC-PUFA from fish or 
fish oil with no further benefit beyond 250 mg.d-1 (Mozaffarian and Rimm 2006)). Moreover, 
secondary prevention of heart disease deaths has been achieved in clinical trials with low 
intakes of fish oil omega-3 fatty acids (<1g.d-1) despite little change in the classical 
cardiovascular risk factors of blood pressure or triacylglycerols (Burr et al. 1989; Valagussa 
et al. 1999; Tavazzi et al. 2008). The large prospective cohort studies: the Physicians Health 
study (Albert et al. 1998); and the Zutphen Study (Kromhout et al. 1985; Streppel et al. 
2008), both observed the primary prevention of cardiovascular deaths with 1-2 fish meals per 
week, and found that the omega-3 LC-PUFA intake was associated with reduced risk of 
sudden arrhythmic death.  This reduced risk of sudden death was, on the one hand, not 
associated with reduced risk of myocardial infarction (Albert et al. 1998), and on the other 
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hand, unlikely to be associated with effects on lipids and lipoprotein metabolism, platelet 
aggregation or bleeding time (Kromhout et al. 1985). An alternative mechanism of action to 
platelet function, blood pressure regulation or blood lipids and atherosclerosis must be sought 
to fully explain the consistent cardiovascular benefits associated with the moderate 
consumption of fish.   
2. A CARDIAC BASIS FOR OMEGA-3 ACTIONS 
2.1. Cardiac Arrhythmia 
In both the general population and in high risk cardiac patients, consumption of omega-3 LC-
PUFA is associated with fewer cardiac deaths. There is a particularly high risk of sudden 
arrhythmic death in the first 5 years after a heart attack (myocardial infarction), making this 
an ideal target population for studying prevention of fatal arrhythmias.   The Diet and 
Reinfarction Trial, a secondary prevention trial of  2033 men who had recovered from a 
myocardial infarction, reported reduced cardiovascular mortality with regular intake of 2-3 
portions of fatty fish per week (Burr et al. 1989), which because there was no significant 
difference in new ischaemic events, was indicative of the prevention of arrhythmic sudden 
death.  Similarly, a large secondary prevention trial of more than 11,000 high-risk patients 
post-myocardial infarction (GISSI Prevenzione trial), used the specific endpoint of sudden 
death and demonstrated lower mortality rates associated with 850 mg.d-1 of EPA+DHA in 
capsule form (Valagussa et al. 1999). In these large clinical trials, the mortality benefit was 
achieved without reduction in new ischaemic events (i.e. no fewer new heart attacks but 
fewer deaths).  In the GISSI Prevenzione trial the reduction in risk of sudden cardiac death 
was evident within 120 days of starting supplementation, compared with double that time for 
mortality from other cardiovascular causes (Marchioli et al. 2002).  Together with 
epidemiological evidence of the primary prevention of sudden death with regular fish 
consumption in case-controlled (Siscovick et al. 1995) and cohort (Albert et al. 1998; 
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Streppel et al. 2008) observational studies, the mechanisms of benefits of modest intakes of 
fish oil fatty acids have diverged from effects on plasma lipids, vascular disease and 
ischaemic events that represent one grouping of mechanisms of action (Kromhout et al. 
2012). Other possible mechanisms however, converge with a large body of physiological 
evidence from animal dietary studies demonstrating prevention of heart failure (Duda et al. 
2007; McLennan et al. 2012), and in vivo antiarrhythmic effects in several species, including: 
rat (Hartog et al. 1987; McLennan et al. 1988; Gudbjarnason 1989; McLennan et al. 1989a; 
Hock et al. 1990; McLennan et al. 1990; McLennan 1993; al Makdessi et al. 1995); pig 
(Hartog et al. 1987); and marmoset monkey (McLennan et al. 1992b, 1993). Furthermore, the 
in vitro perfused heart studies illustrate the direct intra-cardiac (intrinsic) arrhythmia and 
heart failure prevention and heart rate slowing are not dependent upon circulating fatty acids 
(Pepe and McLennan 1996; Abdukeyum et al. 2008; McLennan et al. 2012). 
2.1.1. Heart Rate variability 
Physiological evidence supporting the antiarrhythmic action of fish oil fatty acids is also 
derived from the association of omega-3 fatty acid consumption with increased heart rate 
variability (HRV) (Christensen et al. 1999; Christensen et al. 2001a; Christensen et al. 2001b; 
Villa et al. 2002) (Xin et al. 2013) and with lower heart rate (Vandongen et al. 1993; 
Christensen et al. 1999; Mozaffarian et al. 2005c).  
 
Heart rate variability applies a variety of metrics to describe the oscillations in heart period of 
consecutive beats, and the oscillations of heart rate over time (Camm et al. 1996; Kleiger et 
al. 2005). Physical activity and emotion have well known influences on heart rate, however 
even at rest, with a settled mean heart rate, the heart period fluctuates from beat to beat due to 
a dynamic interplay between multiple physiologic control mechanisms, providing fine tuning 
to cardiac output and mean arterial blood pressure. Short term regulation is under the constant 
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influence of parasympathetic and sympathetic neural activity, and other neurohormonal and 
circadian rhythms modulate heart rate over time.  The major HRV metrics can be categorised 
within time and frequency domains (Kleiger et al. 2005).  Importantly from an applied 
physiology perspective, high HRV is associated with exercise training, fitness and health, 
whereas low HRV is associated with stress, fatigue, heart failure and is proposed as a marker 
of risk of sudden arrhythmic death (Bilchick et al. 2002), being strongly associated with 
sudden death in post-myocardial infarction cardiac patients.  Various high cardiac risk patient 
groups (chronic renal failure, diabetes mellitus type I, or patients with coronary artery 
disease), exhibit low HRV, which is modulated in association with omega-3 LC-PUFA from 
the diet (Christensen et al. 2001a; Christensen et al. 2001b; Villa et al. 2002; Carney et al. 
2010; Christensen et al. 2010).  Post-myocardial infarction patients also exhibit increased 
HRV after dietary intervention with marine lipids (Christensen et al. 1996; Christensen et al. 
1997; O'Keefe et al. 2006; Mozaffarian et al. 2008) as do healthy men (Christensen et al. 
1999).  In a large cohort of over 5000 men and women aged >65 y, habitual fish 
consumption, providing omega-3 LC-PUFA intake over a normal dietary range (300-500 
mg.d-1) and higher, was associated with improved HRV, particularly in parameters indicating 
augmented vagal activity and reduced erratic sinus node firing (Mozaffarian et al. 2008).  A 
systematic review and meta-analysis of nine separate fish oil intervention studies identified a 
significant increase in high frequency power indicative of increased vagal tone (Xin et al. 
2013).  In many respects, the omega-3 LC-PUFA appear to reduce heart disease risk similarly 
to regular exercise (Brown and Moore 2007; Marini et al. 2007; Powers et al. 2008) and 
improved HRV is another factor held in common between dietary fish oil and exercise 
training (Amano et al. 2001; Nunan et al. 2010; Grant and van Rensburg 2013). 
2.1.2. Intrinsic Heart Rate 
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Physiologically, slowing the heart rate increases ventricular filling time and allows 
myocardial stretch to improve ejection force with less energy cost than sympathetic 
stimulation, improving cardiac efficiency.  Clinically, this principle is utilised through the use 
of -blockers in treatment of hypertension and heart failure.  A change in heart rate has little 
impact on early rapid filling or late atrial filling but correlates very closely with diastasis, the 
middle phase of ventricular filling (Chung et al. 2004).  Coronary blood flow is greatest in 
this period of diastole and slower heart rate has implications for coronary perfusion reserve 
and more efficient myocardial perfusion.  Conversely, a high resting heart rate is a marker of 
elevated risk for cardiovascular mortality, particularly sudden death and heart failure (Kannel 
et al. 1987; Fox et al. 2007).  Regular omega-3 LC-PUFA intake can lower resting heart rate 
by up to 5 beats per minute in patient and healthy populations (Grimsgaard et al. 1998; Mori 
et al. 1999; Dallongeville et al. 2003; Geelen et al. 2005; O'Keefe et al. 2006), in healthy 
individuals during exercise without compromising maximum heart rate (Peoples et al. 2008), 
and during exercise recovery in post-myocardial infarction patients (O'Keefe et al. 2006). 
Meta-analysis of randomised control trials with heart rate recorded as a secondary outcome 
found an average reduction of 2.5 beats per minute with fish oil supplementation 
(Mozaffarian et al. 2005c).  Fish oil dietary-induced heart rate slowing is exhibited across 
many animal species, including: horse (O'Connor et al. 2004); pig (Hartog et al. 1987); rabbit 
(Verkerk et al. 2009a); and dog (Billman and Harris 2011), which together with the human 
evidence and a non-significant trend in marmoset monkey (McLennan et al. 1992a), provides 
evidence for a universal heart rate lowering effect of dietary omega-3 LC-PUFA (McLennan 
and Abeywardena 2005).  The omega-3 LC-PUFA and exercise training share the ability to 
reduce resting heart rate.  While heart rate and heart rate variability largely reflect the activity 
and balance of the autonomic nervous system, an intrinsic effect within the myocardium is 
evident from the ability of chronic fish oil feeding to reduce heart rate in human cardiac 
transplant patients (Harris et al. 2006); in rat isolated heart (Abdukeyum et al. 2008); and in 
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rabbit isolated pacemaker cells (Verkerk et al. 2009a), which in the absence of neural input 
illustrates an independence from autonomic control that is similarly demonstrable for 
arrhythmia prevention (Yang et al. 1993; Pepe and McLennan 1996; Abdukeyum et al. 2008).  
 
Automaticity due to change in pacemaker potential during diastolic depolarisation is 
primarily ascribed to two ionic mechanisms: the pacemaker current attributed to channels 
permeable to both Na+ and K+ (funny current (If)); or to Ca
2+ transients, most recently 
ascribed to intracellular Ca2+ cycling (Vinogradova and Lakatta 2009; Monfredi et al. 2013).  
The slowed heart rate in vitro in rabbits after dietary fish oil modulation has been partly 
explained by reduced If density and pacemaker activity in sinoatrial cells, however there 
remains residual activity, which implicates other membrane currents in the omega-3 LC-
PUFA effects (Verkerk et al. 2009a).  To date, the effects of omega-3 LC-PUFA on other 
specific ion channels in pacemaker cells have not been studied, however omega-3 LC-PUFA 
do influence a number of ion channels in non-pacemaker cardiac muscle cells and other cell 
types (McLennan 2004; Xiao et al. 2005) which are further considered below. 
2.2. Cardiac function in healthy and failing heart 
In addition to effects mediated through altered physiology of cardiac excitability and 
spontaneous depolarisation rate, clinical and experimental studies reveal prevention of heart 
failure as a further potential mechanism of fish oil action.  A large epidemiology study of 
4,738 adults aged over 65 y that showed 20% reduced incidence of heart failure associated 
with fish meals delivering estimated intakes of omega-3 LC-PUFA as low as 260 mg.d-1 
(Mozaffarian et al. 2005b), directly implicates effects on heart function whilst indirect 
evidence can be found in the reduced non-arrhythmic but otherwise unspecified cardiac 
deaths and post-infarction deaths (Valagussa et al. 1999). More recently, a randomised 
controlled trial in 6,975 patients with heart failure showed that 850 mg.d-1 of EPA+DHA 
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reduced mortality and cardiac cause hospitalisations, with specific improvement in the 
proportion of subjects with low (<40%) ejection fraction (Tavazzi et al. 2008).  Furthermore, 
a large cohort trial in general practice recruited 12,500 patients with multiple cardiovascular 
disease risk factors, and reported a 35% reduction in hospitalisations from heart failure as the 
only physiologically and clinically meaningful outcome from treatment with 850 mg.d-1 
EPA+DHA over 5 years (Risk and Prevention Study Collaborative Group 2013).  These 
outcomes reflect improved myocardial function in clinical populations, and as with sudden 
cardiac death, they occur independently of dietary omega-3 LC-PUFA effects on classic risk 
factors such as plasma triacylglycerols and thrombogenic factors (Nordoy et al. 2001).  
Again, physiological roles within cardiac membranes are implicated.  Animal studies 
describe fish oil-induced improvements in myocardial inotropy, lusitropy and efficiency of 
oxygen use by the myocardium that are associated with the incorporation of the omega-3 LC-
PUFA DHA into myocardial membranes (McLennan et al. 1992a; Pepe and McLennan 2002, 
2007; Abdukeyum et al. 2008). These have been translated into direct demonstration of 
improved contractility and sustained cardiac output in hypertrophy models of heart failure 
(Duda et al. 2007; McLennan et al. 2012) . 
2.3. Membrane composition as a basis for omega-3 fatty acids cardiac effects. 
In the laboratory rat, dietary fish oil (EPA+DHA: 1.75-4% of diet by weight or 3.5-8% of diet 
energy) produces marked changes in myocardial membrane phospholipid fatty acid 
composition, increasing the content of omega-3 LC-PUFA especially DHA and reducing the 
content of omega-6 PUFA arachidonic acid and linoleic acid (Charnock et al. 1986; Hartog et 
al. 1986; Hartog et al. 1987; McLennan et al. 1993; al Makdessi et al. 1995; McLennan et al. 
1996; Pepe and McLennan 1996; McLennan 2001).  The intakes employed historically are 
mostly unachievable in the equivalent human diet, raising questions of their relvance to 
human physiology.  It was more recently established that maximal omega-3 LC-PUFA 
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incorporation is derived from smaller dietary intakes (EPA+DHA: 0.5-0.75% by weight or 1-
1.5% energy) (McLennan et al. 1996; Owen et al. 2004).  Notably from an applied 
physiology perspective, very small intakes in the rat (EPA+DHA: 0.05-0.2% by weight or 
0.1-0.5% energy) can double to triple the myocardial membrane omega-3 LC-PUFA content 
almost to maximal incorporation, and this translates to 280 – 1200 mg.d-1 for human 
consumption (Slee et al. 2010).  Thus, physiological outcomes in the rat, can now be regarded 
as consistent with those observed in human populations, having dietary fish intakes 
associated with: reduced risk of sudden cardiac death (EPA+DHA: 100-450 mg.d-1 
(Siscovick et al. 1995); EPA+DHA: 250 mg.d-1 (Mozaffarian and Rimm 2006)); reduced risk 
of incident heart failure (EPA+DHA: 250 mg.d-1 (Mozaffarian et al. 2005b); EPA+DHA: 100 
– 400 mg.d-1 (Wilk et al. 2012)); and lower heart rates (fish more than once per week: 
EPA+DHA: 250 - >500 mg.d-1 (Mozaffarian et al. 2006); fish more than once per week 
(Dallongeville et al. 2003)).  It is likely therefore, that the omega-3 fatty acids exert their 
protective effects by their role in the fabric of the heart, affecting intrinsic myocardial 
physiology (McLennan et al. 2007) to modify sinoatrial node function, myocardial 
depolarisation and electrical stability, contractility and relaxation (Figure 2).  Additional 
effects on risk factors of plasma lipids and blood pressure occur only at higher 
(pharmacological or therapeutic) intakes in excess of EPA+DHA 3 g.d-1  (Skulas-Ray et al. 
2011; Cabo et al. 2012) (Figure 2).  
[Figure 2 near here]  
2.4. Ongoing controversy on cardiovascular disease protection by fish oil fatty acids. 
Not all reviews of the evidence determine a cardioprotective role of fish oil fatty acids.  A 
comprehensive systematic review and meta-analysis raised some doubts about fish oil 
cardiovascular protection (Hooper et al. 2006; Hooper et al. 2009), but becomes quite 
revealing on sub-analysis to unpick the pooled clinical endpoints.  With some endpoints, 
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effects seen in cohort studies were not reproduced in randomised controlled trials and these 
differences might be explained by the different sources of omega-3 LC-PUFA derived from 
the diet as opposed to supplements.  While it is well established that food fish typically 
contain DHA in excess of EPA (Nichols et al. 1998; Kris-Etherton et al. 2002; Mozaffarian 
and Wu 2011), this has largely been ignored in designing clinical trials, where fish oil 
supplements predominantly provide EPA in excess of DHA.  Furthermore, the cardiovascular 
events, of stroke, non-fatal myocardial infarction and vascular restenosis, which show less or 
no trend towards favouring fish oil can be attributed to vascular and lipid metabolism, 
whereas the cardiovascular events of fatal myocardial infarction, heart failure, and sudden 
cardiac death not only show trends in randomised control trials but significant effects of 
cohort studies on meta-analysis (Hooper et al. 2009; Xin et al. 2012) and can be attributed to 
intrinsic effects within the heart (Figure 2). 
 
Why is this important?  Sudden cardiac death accounts for many thousands of deaths 
annually in developed nations. Transient changes such as myocardial ischemia, or electrolyte 
imbalance can precipitate ventricular fibrillation (Myerburg et al. 1989).  A great proportion 
of ischaemic episodes progress to myocardial infarction, which produces a vulnerable 
myocardial substrate, waiting for a trigger event for lethal arrhythmias to occur. The basis for 
subtle differences in vulnerability that may predispose the sudden death victim to fatal 
arrhythmia is not well understood (Huikuri et al. 2003), however experimental observations 
in acute ischaemia (McLennan et al. 1993), human intervention trial in patients with an 
existing myocardial infarction (Marchioli et al. 2002), and a case control study of primary 
cardiac arrest (Siscovick et al. 1995) suggests that omega-3 LC-PUFA stabilise the 
vulnerable myocardium and reduce the risk of the trigger causing arrhythmia. The GISSI 
Prevenzione trial recruited patients within two to three weeks of their index myocardial 
infarction and found the increased vulnerability amenable to omega-3 LC-PUFA was most 
 17
evident early, with 57% of the mortality benefit achieved within 90 d (Marchioli et al. 2002).  
Clinical trials such as the SU.FOL.OM3 trial, which investigated post myocardial infarction 
patients (potential vulnerable myocardial substrate) pooled together with those more at risk of 
vascular occlusion and ischaemic stroke (Galan et al. 2011) are likely to be underpowered to 
detect intrinsic cardiac mechanisms of omega-3 PUFA action and prevention of sudden 
cardiac death.  By recruiting patients up to 12 months after their index event (median 101 d) 
the acute vulnerable period identified in GISSI Prevenzione may have also been missed. 
3. SELECTIVITY AND SPECIFICITY OF OMEGA-3 EFFECTS 
The cardiovascular protective effects of fish oil are not reproducible with dietary ALA as the 
source of omega-3 PUFA (Mozaffarian 2005; Mozaffarian and Wu 2011; Vedtofte et al. 
2011).  This confirms both the poor conversion of ALA to DHA (Brenna et al. 2009) and 
reflects the low presence of circulating ALA in plasma phospholipid (Gibson et al. 2013) and 
the extremely low concentration or absence of ALA in human (Sexton et al. 1995) or animal 
(McLennan and Dallimore 1995) cardiac tissue samples. Human studies do not readily afford 
biopsy of heart muscle to correlate composition with fish oil or omega-3 fatty acid 
consumption.   Numerous animal studies report that DHA is the most abundant omega-3 fatty 
acid found in myocardial membrane phospholipids, with EPA often undetectable in rat heart 
unless supplemented with fish oil  (Hartog et al. 1986; Gudbjarnason 1989; Hock et al. 1990; 
Woodcock et al. 1995; Pepe and McLennan 1996; Honen and Saint 2002; Pepe and 
McLennan 2002; Arnold et al. 2010; Slee et al. 2010).  Similarly, marmoset monkey 
(Charnock et al. 1989; Charnock et al. 1992) and pig (Nair et al. 2000; Coronel et al. 2007) 
display higher myocardial concentrations of DHA than EPA prior to fish oil feeding.    Fish 
and fish oil contain both EPA and DHA, however fish oil feeding in the rat favours 
myocardial enrichment with DHA.  This occurs irrespective of whether a high EPA fish oil 
(Hartog et al. 1986; Gudbjarnason 1989; Hock et al. 1990; Woodcock et al. 1995; Pepe and 
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McLennan 1996; Honen and Saint 2002; Pepe and McLennan 2002; Arnold et al. 2010) or a 
DHA rich fish oil is consumed, at high (5-12% of diet by weight) (Charnock et al. 1986; 
McLennan et al. 1993; McLennan 2001) or low (0.16-1.25%) intakes (Slee et al. 2010).  
Similar excess of DHA over EPA is found in the myocardium of a non-human primate the 
marmoset monkey after fish oil feeding (Charnock et al. 1992).  In contrast, pigs fed a high 
EPA fish oil or equal concentrations of EPA and DHA show markedly greater myocardial 
enrichment of EPA than DHA (Nair et al. 1999; Nair et al. 2000; Coronel et al. 2007).  
Similar to the pig, dog hearts are peculiarly resistant to incorporation of DHA (Judé et al. 
2007; Billman et al. 2010).  Dog ventricle shows greater enrichment with EPA than DHA 
after 12 w of  4 g.d-1 fish oil ethyl ester concentrate, delivering 3360 mg.d-1 EPA+DHA to 20 
kg dogs (Billman et al. 2010) or even after feeding a high DHA dietary supplement delivering 
456 mg.d-1 EPA+DHA  for 8 w (Judé et al. 2007).  However in the rat, even feeding a diet 
enriched with purified EPA produces a greater increase in membrane phospholipid DHA 
content with little incorporation of EPA (McLennan et al. 1996; McLennan and Raederstorff 
1999).  This contrasts with the direct incubation of isolated myocytes with EPA which results 
in EPA enrichment of the membrane fatty acids (deJonge et al. 1996a).  In dietary studies the 
enrichment of myocardial DHA even occurs against a background of high circulating total 
plasma EPA in the rat (McLennan 2001) and with high or low background omega-6 PUFA 
(Slee et al. 2010).   
 
Whilst few in number, analyses of both human ventricle and human atria consistently report 
DHA incorporation at markedly higher concentrations than EPA (Rocquelin et al. 1985; 
Sexton et al. 1995; Garg et al. 2006; Metcalf et al. 2007; Metcalf et al. 2010).  Atria, which 
are the most often sampled human myocardial tissue, sustain DHA enrichment well above 
EPA after fish oil supplementation, with concentrations of DHA reaching 8-10%  compared 
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with maximum of 2-4% EPA (Garg et al. 2006; Metcalf et al. 2007; Metcalf et al. 2010)}, 
implicating a primary role for DHA in human cardiac physiology, as in the rat.   
 
In contrast to myocardium, detailed fatty acid composition is more readily available from 
human plasma, red blood cell and skeletal muscle. Rat and marmoset monkey studies report 
that the composition of skeletal muscle phospholipid fatty acids closely resemble heart, 
having high DHA and low EPA concentrations irrespective of the background diet (Charnock 
et al. 1989; Charnock et al. 1992; Helge et al. 1999) and respond to fish oil feeding by 
increasing DHA incorporation (Peoples and McLennan 2010).  Similarly, human adult or 
infant skeletal muscle also incorporates more DHA than EPA under a variety of conditions 
(Borkman et al. 1993; Baur et al. 2000; Di Marino et al. 2000; Helge et al. 2001).  Holub and 
co-workers, in a series of studies of Canadian Inuit, Cree, and residents of Quebec and 
Guelph found that irrespective of fish intake, DHA exceeds EPA in plasma phospholipids 
(Dewailly et al. 2001a; Dewailly et al. 2001b; Conquer et al. 2002; Dewailly et al. 2002) even 
when relative intakes of EPA and DHA are very similar (Dewailly et al. 2001a).  Finally, red 
blood cell fatty acid composition and the concentration sum of EPA+DHA  has been 
proposed as a risk factor for cardiovascular disease, the omega-3 index (Harris and von 
Schacky 2004), acting as a biomarker of omega-3 PUFA status that correlates well with 
myocardial omega-3 LC-PUFA content in man (Metcalf et al. 2010) and rats (Owen et al. 
2004; Stark 2008).  Dietary supplementation of healthy young adults for five months with 
fish oil containing EPA in excess of DHA, resulted in dose related increases in red blood cell 
omega-3 index (Flock et al. 2013b).  At all doses of fish oil, up to 1800 mg.d-1, despite an 
excess of EPA over DHA, the red blood cell membrane concentration of DHA increased 
more, and always exceeded that of EPA (even with placebo), confirming many other reports 
of higher DHA than EPA concentrations in human red blood cells (Stark 2008; Metcalf et al. 
2010; Flock et al. 2013a; Patterson et al. 2014).   Dietary supplementation of animals and 
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humans also demonstrates selectivity of DHA over EPA for lowering heart rate (Grimsgaard 
et al. 1998), lowering blood pressure and improving vascular reactivity (enhancing 
vasodilator and attenuating vasoconstrictor responses) (McLennan et al. 1996; Mori et al. 
1999; Mori et al. 2000). While these studies suggest a small negative association between 
plasma lipid risk factors (HDL/ total cholesterol, triacylglycerols) and omega-3 LC-PUFA 
that appear to be slightly stronger for EPA than DHA, there is often little change in these 
factors at doses associated with the reduced incidence of sudden cardiac death (Burr et al. 
1989; Siscovick et al. 1995; Albert et al. 1998; Valagussa et al. 1999; Marchioli et al. 2002; 
Lemaitre et al. 2003).  Contrast that with the JELIS study (Yokoyama et al. 2007), which 
delivered 1800 mg.d-1 of pure EPA supplement to hypercholesterolaemic patients and 
identified significant reduction in vascular / lipid related events but no difference in sudden 
cardiac death, implicating EPA in extrinsic but not intrinsic effects of fish oil.  
4. ELECTROPHYSIOLOGICAL EFFECTS OF OMEGA-3 FATTY ACIDS. 
When considering cellular mechanisms underpinning the effects of dietary inclusion of fish 
oil on cardiac function and risk, there are two primary considerations:  
 Dietary fish deliver DHA as the principal omega-3 fatty acid. 
 The human myocardium selectively incorporates DHA over EPA. 
From these observations, two conditions should be met in interpreting in vitro and in vivo 
studies of physiological mechanisms in order to explain the association of omega-3 LC-
PUFA consumption with clinical outcomes in population and dietary intervention studies. 
 Effects of acutely administered fatty acids on ion channels or intracellular 
mechanisms must be reproducible with dietary intervention and membrane 
incorporation. 
 Effects attributable to the omega-3 PUFA must be specific and not reproduced by 
omega-6 PUFA, solvents or detergents. 
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4.1. Whole animal: 
In order for the putative intrinsic antiarrhythmic and cardiac slowing actions of dietary 
omega-3 LC-PUFA to be fully accepted, a physiologically plausible mechanism of action 
needs to be substantiated (Tang and Samara 2011).   In particular, for a sound basis in 
physiology nutritional effects must be distinguished from a selective acute therapeutic effect 
or a laboratory curiosity (i.e. can effects obtained from acute ingestion replicate effects of 
habitual consumption). Acute exposure to omega-3 fatty acids prevents cardiac arrhythmias 
in vivo and dysrhythmias of isolated myocytes in vitro.  Ventricular fibrillation is inducible 
on demand in dogs with an existing myocardial infarction by acute coronary occlusion while 
they are exercising (Billman et al. 1994; Billman et al. 1997).  This is a reliable and 
reproducible stimulus for arrhythmias which can be tested and re-tested between treatments 
and in recovery. The combined stress of acute coronary artery occlusion and exercise 
(ischaemia plus sympathetic stimulation) induces arrhythmias which are prevented by acute 
infusion of fish oil fatty acid emulsions (Billman et al. 1994; Billman et al. 1997).   In this 
post-infarction model of sudden death, individual fatty acid emulsions of EPA, DHA or ALA 
were equally effective in preventing ventricular fibrillation (Billman et al. 1999).  In 
comparison, an emulsion rich in omega-6 PUFA linoleic acid had no antiarrhythmic effect 
(Billman et al. 1994; Billman et al. 1997, 1999).  However, the arrhythmia prevention was 
accompanied by an acute fall in heart rate of greater than 20%  together with a marked 
prolongation of the ECG QRS complex, P-R interval and outright 2nd degree heart block in 
half of the dogs treated with a fish oil emulsion (Billman et al. 1994).  These findings 
demonstrate significant electrophysiological perturbations to the heart that perhaps underpin a 
powerful acute antiarrhythmic effect of omega-3 fatty acids, but probably do not explain the 
physiological basis for arrhythmia prevention and reduced cardiovascular mortality with 
regular fish consumption. For one thing, the lack of selectivity for different omega-3 PUFA 
contrasts to dietary studies that show purified DHA or EPA+DHA but not EPA alone are 
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antiarrhythmic at low dietary intakes (McLennan et al. 1996) and whereas dietary ALA 
exhibits some antiarrhythmic efficacy at high intakes of canola oil, it is not effective when 
delivered as soybean oil, demonstrating that incorporation of DHA, not circulating ALA is 
required (McLennan and Dallimore 1995).  Meta-analysis shows that, unlike omega-3 LC-
PUFA from fish oils, ALA has no significant effect overall on ischaemia or reperfusion 
induced arrhythmias in animal studies (Matthan et al. 2005) or in the human diet 
(Mozaffarian 2005) .  
The acute infusion findings using the post-myocardial infarction dog model, recently 
translated into dietary studies, which not only did not replicate the antiarrhythmic effect of  
acute fish oil or omega-3 PUFA infusion, but rather perversely revealed a pro-arrhythmic 
effect of a high dietary intake (3360 mg.d-1 EPA+DHA) (Billman et al. 2010). While the 
report acknowledged that the dietary intake responsible for the increased risk of ventricular 
fibrillation was well beyond human dietary intakes (20 kg dog given equivalent of 13,440 
mg.d-1 EPA+DHA for an 80 kg man), maximum incorporation of DHA into myocardium was 
achieved already with the (840 mg.d-1) lowest of three dietary doses and further increases in 
membrane omega-3 LC-PUFA were primarily attributable to an exponential rise in EPA 
incorporation (Billman et al. 2010).  The incorporation of DHA into the myocardial 
membranes of the dogs is very low compared to other animals and low even compared to 
human, with or without dietary supplementation (Rocquelin et al. 1985; Sexton et al. 1995; 
Garg et al. 2006; Metcalf et al. 2007; Metcalf et al. 2010).  One human exception is found in 
the composition of biopsies from heart transplant patients during fish oil supplementation, 
which demonstrated much lower incorporation of omega LC-PUFA than expected, based on 
other human samples, more akin to buccal epithelial (cheek) cells and less than in red blood 
cell membranes of the same patients (Harris et al. 2004).  By virtue of the sampling technique 
that obtained a very small biopsy of the interventricular septum for the purpose of checking 
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for tissue rejection, the sample may be more representative of endothelial cells than the 
excitable myocardium.   Therefore, it would appear that the dog, whilst a good model of 
myocardial infarction and ischaemic arrhythmias, is a poor model for investigating the 
physiological effects of dietary omega-3 LC-PUFA incorporation into myocardium. 
4.2. Effects of omega-3 fatty acids on cardiac and cellular electrical excitability 
 The acute administration of purified fatty acids has a wide range of electrophysiological 
effects in isolated cell systems and an equally wide range of interactions with arrhythmic 
stimuli and modulators of cellular electrophysiology that could contribute to their effects on 
arrhythmia vulnerability, spontaneous beat rate, contractility and relaxation.  These ion 
channels are involved in the genesis and/or maintenance of cardiac action potentials and 
controlling intracellular stores of Ca2+.  They include: Na+ currents (INa+), K
+ currents 
(delayed rectifier IK+), transient outward current (ITO)) (Judé et al. 2003), and Ca
2+ current 
(ICa2+ ) (Table 1).  
[Table 1 near here] 
Isolated myocytes are commonly used for electrophysiological research and have been used 
extensively to investigate mechanisms of antiarrhythmic effects of omega-3 LC-PUFA.  
Many observations using isolated cardiomyocytes appear to replicate the acute depressant 
effects that omega-3 PUFA have on cardiac excitability and conduction after infusion into 
dogs in vivo (Billman et al. 1994). Isolated myocardial cells acutely exposed to omega-3 LC-
PUFA become electrically less excitable. Effects such as extreme reduction in the 
spontaneous beat rate and induction of a slow and sporadic spontaneous contraction pattern 
(Kang and Leaf 1994, 1995, 1996c, b) are commonly reported (Table 2). When exposed to 
omega-3 LC-PUFA, these cells require higher stimulation voltages to capture and drive them 
at a faster beat rate, and exhibit a much lower maximum following-frequency than control 
cells (Kang and Leaf 1996c).  Moreover and perhaps most telling, these acute 
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electrophysiological effects are shared by all PUFA, including omega-6 PUFA linoleic acid 
and arachidonic acid.  Thus there is little apparent selectivity for the purified omega-3 LC-
PUFA (Kang and Leaf 1994, 1995; Kang et al. 1995; Kang and Leaf 1996c) (Table 2.).   
[Table 2. near here] 
In contrast, cardiomyocytes incubated with EPA or DHA for at least three days exhibit little 
change in basal spontaneous contractions, yet become protected from the intracellular Ca2+ 
overload and tachyarrhythmias induced by incubation with the Na+ pump inhibitor ouabain or 
the Ca2+ channel agonist BayK8644 (Hallaq et al. 1990; Hallaq et al. 1992).  Chronic 
incubation of myocytes with omega-3 LC-PUFA therefore produces effects akin to dietary 
intervention, with no evidence of the depressed electrical excitability that occurs with acute 
administration of omega-3 LC-PUFA to cellular incubates or by acute infusion into the dog in 
vivo.  Programmed stimulation of ventricular fibrillation in the marmoset heart in vivo, is 
inhibited after chronic fish oil feeding (inducible fibrillation threshold current is higher), but 
the stimulation voltage required to capture and drive the ventricles above their spontaneous 
beat rate (electrical excitability) is not affected (McLennan et al. 1993).  Nor is capture 
voltage (electrical excitability) in isolated rat hearts influenced by a fish oil diet, although the 
current needed to trigger inducible ventricular fibrillation in programmed stimulation is 
raised significantly (Pepe and McLennan 1996).  Consequently, the chronic incorporation of 
omega-3 LC-PUFA into myocardial membranes appears to inhibit triggered arrhythmias 
without depressing basal excitability or electrical conduction. 
4.2.1. Effects of omega-3 fatty acids on myocardial Na+ channel function, K+ 
channel function and arrhythmia 
A variety of ion channels contribute to the mammalian action potential, and their modulation 
has the potential to modify heart rate (spontaneous activation rate) of autorhythmic 
“pacemaker” cells or arrhythmogenesis in non-autorhythmic cells (Rosen 1991; Lakatta et al. 
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2010; Rosen and Janse 2010).  These channels control ionic currents that create, sustain and 
curtail cardiac action potentials by the sequential opening and closing of: fast voltage-
dependent Na+ channels to initiate an action potential; an outwardly directed K+ current 
(transient outward current (ITO)) to stabilise the positive membrane potential; a temporarily 
sustained inward ICa2+ to sustain the action potential plateau; and a second outward current 
(delayed rectifier) IK+, which moves K
+ out of the cell, repolarising the myocyte to its resting 
membrane potential (Table 1).  
 
Cellular electrophysiological studies reveal that EPA and DHA acutely inhibit the ventricular 
sodium current (INa+).  They reduce the current amplitude in neonatal myocardial cells (Xiao 
et al. 1995), markedly reduce the inactivation voltage and more rapidly restore Na+ channel 
inactivation in neonatal or adult myocytes (Xiao et al. 1995; Leifert et al. 1999; Xiao et al. 
2004) increase the activation voltage.  They also inhibit Na+ channel ligand binding (Kang 
and Leaf 1996a). It is postulated that a persistent INa+ could underpin ischaemic arrhythmias, 
and omega-3 LC-PUFA powerfully block Na+ channels in non-cardiac cells transfected with 
a mutant, inactivation-deficient, human myocardial Na+ channel (Xiao et al. 2006).  However, 
just as chronic incorporation of omega-3 LC-PUFA does not reduce myocyte electrical 
excitability, the Na+ channel specific binding is not inhibited after 3 days of cellular 
incubation (Kang et al. 1997), and three weeks of fish oil feeding prior to myocyte isolation 
does not increase membrane INa+ activation voltage and has only a minor effect on 
inactivation voltage (Leifert et al. 2000b) (Table 1).  Therefore, both prolonged cellular 
incubation with omega-3 LC-PUFA and fish oil pre-feeding retain their antiarrhythmic 
effects (Table 1) in isolated myocytes, independently of effects on Na+ channels, (Kang et al. 
1997; Leifert et al. 2000b) (Table 2).  
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Acute presentation of EPA or DHA to adult isolated cardiomyocytes alters membrane fluidity 
and the altered INa+ properties are mimicked by the membrane fluidiser benzyl alcohol (i.e. 
Na+ channel blocking activity of the  acutely added omega-3 LC-PUFA correlates with 
changes in membrane fluidity) (Leifert et al. 1999; Jahangiri et al. 2000; Leifert et al. 2000a).  
However, adult cardiomyocytes isolated from fish oil fed (arrhythmia protected) rats do not 
display any measurable increase in membrane fluidity (Leifert et al. 2001) and yet retain their 
antiarrhythmic protection in vitro.  There may however be some differences between neonatal 
and adult myocytes because enrichment of membrane phospholipids by 3 days of incubation 
with EPA did produce an increase in membrane fluidity in neonatal cells (deJonge et al. 
1996a).  Nevertheless, the balance of evidence suggests that neither the Na + channel nor 
membrane fluidity effects of acutely administered omega-3 LC-PUFA are sufficient to 
explain the in vitro or in vivo antiarrhythmic effects of the fatty acids incorporated into cell 
membrane phospholipid.   
 
Further evidence that the electrophysiological changes in Na+ channels and electrical 
excitability may be non-specific comes from the common observation that the omega-6 
PUFA linoleic acid, arachidonic acid and the non-metabolisable analogue eicosatetraynoic 
acids (ETYA) are often equally effective with omega-3 LC-PUFA, and their effects are 
mimicked by benzyl alcohol (Honore et al. 1994; Xiao et al. 1995; Kang and Leaf 1996a; 
Xiao et al. 1998; Leifert et al. 1999; Xiao et al. 2006).  Antiarrhythmic effects of omega-6 
PUFA relative to dietary saturated fat in coronary artery occlusion animal models are long 
established (Lepran et al. 1981; McLennan et al. 1985, 1988, 1989a; McLennan 1993), and 
dietary omega-6 PUFA intake has been associated with a downturn in sudden cardiac death in 
Australia and the USA in the late part of the 20th century (Hetzel et al. 1989). However, in the 
absence of fish oil fatty acids in the diet the omega-6 PUFA are the primary fatty acids in 
myocardial cells in hearts vulnerable to arrhythmic stimuli, and when omega-6 PUFA rich 
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vegetable oils are matched against dietary fish oil directly, the omega-3 LC-PUFA provide a 
demonstrable antiarrhythmic advantage (McLennan et al. 1988; McLennan et al. 1993). 
Dietary studies collectively demonstrate both a general antiarrhythmic affect attributable to 
the relative proportions of PUFA and saturated fat in the diet, and unequivocally that a more 
potent antiarrhythmic effect of fish oil persists independently of a non-specific PUFA effect 
(McLennan and Abeywardena 2005) (Figure 3).  It is therefore unlikely that effects shared by 
linoleic acid and DHA or EPA can explain the specific antiarrhythmic or other 
electrophysiological effects of the omega-3 LC-PUFA.    
 
Only a few studies have focussed on K+ currents as a target for omega-3 PUFA action.  The 
inhibition of ITO by DHA was demonstrated in transfected hamster ovary cells (Singleton et 
al. 1999), and has not been evaluated under dietary conditions with chronic membrane 
incorporation.  The delayed rectifier IK+ has also only been evaluated in transfected cell 
systems (Honore et al. 1994; Guizy et al. 2008), and whilst its amplitude is reduced and 
inactivation enhanced by EPA and DHA, these affects are equally demonstrated for the 
omega-6 LC PUFA arachidonic acid (Table 1). The study of cardiac ion channels transfected 
into other cell types may be particularly problematic when considering factors influenced by 
membrane fatty acid composition, since the membrane composition of different cell types has 
a marked influence on activity of membrane proteins transposed into them, first noted 30 
years ago (Abeywardena and Charnock 1983). The one report on IK+ function in adult 
cardiomyocytes after fish oil feeding found no significant change in activation voltage despite 
chronic membrane compositional change and reduced arrhythmia vulnerability in the same 
celluar system (Leifert et al. 2000b).  Moreover, it was specifically noted that some of these 
acute effects on K+ channels can only be observed when the omega-3 LC-PUFA is applied to 
the extracellular side of the membrane (Guizy et al. 2008) and therefore is unlikely to play a 
role in the action of dietary-derived, membrane incorporated fatty acids.  Fatty acids that are 
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then liberated as intracellular signalling molecules after intracellular phospholipase activation 
(Nair et al. 1997; Siddiqui et al. 2008; Jenkins et al. 2009; Richardson et al. 2011) or 
influence the activity of intracellular signalling proteins such as protein kinase C (Stillwell et 
al. 2005).   
 
Many studies using isolated cell systems, including these experiments on IK+, focus on an 
individual fatty acid (Singleton et al. 1999; Guizy et al. 2008) without controls to detect 
selectivity of or specificity for omega-3 effects.  There is a prevalence of studies evaluating 
EPA  and large gaps in the literature with no data for the principal myocardial omega-3 LC-
PUFA, DHA (Guizy et al. 2008).  The failure to demonstrate specificity prejudices their 
translation to interpretation of physiological dietary effects of omega-3 LC-PUFA with any 
certainty. 
 
The ability of acutely administered omega-3 LC-PUFA to profoundly suppress isolated 
myocyte spontaneous beat rate (Kang and Leaf 1994) or inhibit INa+ activation (Xiao et al. 
2004) is mimicked by the class I antiarrhythmic agent and local anaesthetic lignocaine.  
Delayed conduction, as produced by acute EPA infusion in dogs (Billman et al. 1994), is also 
a characteristic property of lignocaine (Singh et al. 1992).  Importantly, while acute 
administration of omega-3 fatty acids may share these properties with the class I 
antiarrhythmic drugs, there is a contrast in their clinical effectiveness, with the fish oil fatty 
acids reducing the risk of post-infarction sudden death (Valagussa et al. 1999; Marchioli et al. 
2002) but the class I antiarrhythmics increasing the risk through their pro-arrhythmic effects 
(Singh et al. 1992).  The contrasting outcomes of a fish or fish oil intervention trial reducing 
mortality (Burr et al. 1989) while a major class I antiarrhythmic trial (cardiac arrhythmia 
suppression trial) of the same vintage was stopped because of excessive arrhythmic mortality 
(Investigators 1989).  may be instructional. Both were conducted in equivalent post-
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myocardial infarction patients at increased risk of sudden cardiac death.  One caveat is that 
lignocaine (class Ia) is less potent and may not share all properties of the withdrawn class Ic 
drugs of that trial (Williams 1991). The reported pro-arrhythmic action of dietary omega-3 
fatty acids in dogs (Billman et al. 2012) has not been observed in other experimental studies 
or clinical epidemiology but implies potential adverse effects of extremely high intakes, 
producing high membrane incorporation of EPA over DHA (Billman et al. 2010), and this 
may be related to the non-specific block of Na+ channel activity.  
4.2.2. Effects of omega-3 fatty acids on myocardial Ca2+ handling, arrhythmia and 
myocardial function. 
Myocardial ICa2+ not only sustain the action potential plateau, but also provide a window to 
the cell that can lead to intracellular Ca2+ overload, which results from the complex interplay 
between Ca2+ channels, Na+/Ca2+ exchange, sarcoplasmic reticulum Ca2+ uptake, release and 
spillover, and mitochondrial Ca2+ uptake.  Cardiac arrhythmias can be initiated by a variety of 
stimuli that have in common the perturbation of cellular Ca2+ content or handling. 
Arrhythmias generated in isolated myocytes by the Na+ pump inhibitor ouabain, 
catecholamines, elevated extracellular [Ca2+], anoxia, KCl, the Ca2+ ionophore A23187, 
lysophospholipids, Ca2+ channel agonist BayK8644, and hydrogen peroxide, are all 
associated with elevated intracellular Ca2+ [Ca2+]i.  The cellular arrhythmic activity and the 
rise in [Ca2+] i are both prevented by acute application of omega-3 LC-PUFA (Kang and Leaf 
1994, 1996c; Xiao et al. 1997; Rodrigo et al. 1999; Rinaldi et al. 2002) (Table 2).  Similarly, 
Ca2+ overload and cellular Ca2+ transients are inhibited in neonatal cardiomyocytes after 3-5 
days chronic omega-3 LC-PUFA incubation or in adult cardiomyocytes with elevated 
membrane DHA from fish oil feeding (Hallaq et al. 1990; Hallaq et al. 1992; Leifert et al. 
2001; Jahangiri et al. 2006).  The omega-3 LC-PUFA inhibit both L- and T-type Ca2+ 
channels (Pepe et al. 1994; Xiao et al. 1997; Macleod et al. 1998; Rodrigo et al. 1999; 
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Negretti et al. 2000; Danthi et al. 2005; Verkerk et al. 2009b).  Spontaneous intracellular 
“Ca2+ sparks” are reduced in amplitude following either omega-3 LC-PUFA acute application 
(Xiao et al. 1997; Negretti et al. 2000; O'Neill et al. 2002; Honen et al. 2003) or after fish oil 
pre-feeding (Honen et al. 2003).  The Ca2+ sparks originate from the spontaneous release of 
Ca2+ from the sarcoplasmic reticulum with the potential to locally raise the sarcolemmal 
membrane potential to threshold for action potential generation and arrhythmia (Lakatta et al. 
2010; Yaniv et al. 2012; Monfredi et al. 2013).  Fish oil prevents the asynchronous 
contractions and the rise in diastolic [Ca2+]i in electrically driven adult cardiomyocytes 
during hydrogen peroxide superfusion (Jahangiri et al. 2006).   Triggered arrhythmias and 
delayed after-depolarisations induced by rapid pacing of pig cardiomyocytes in the presence 
of noradrenaline are also associated with greater accumulation of sarcoplasmic reticulum 
Ca2+  content, increased Na+/Ca2+ exchange current, and increased L-type ICa2+, all of which 
are inhibited in myocytes derived from pigs fed a fish oil diet (Berecki et al. 2007). In 
contrast, dogs subjected to dietary fish oil but exhibiting no antiarrhythmic effect, also show 
no change in Ca2+ channel activity (Billman et al. 2010), in line with its poor incorporation of 
DHA.   
 
The minimum electrical current required to trigger ventricular fibrillation (ventricular 
fibrillation threshold), is critically dependent on [Ca2+]i (Zaugg et al. 1996) and is elevated in 
fish oil fed marmoset monkeys (McLennan et al. 1993).  In further support of an alteration in 
cellular Ca2+ handling, arrhythmias provoked by ischaemia and reperfusion in the rat isolated 
working heart were abolished by either fish oil feeding (Pepe and McLennan 1996) or the 
sarcoplasmic reticulum Ca2+ release channel blocker ryanodine but not by ruthenium red, an 
inhibitor of mitochondrial Ca2+ uptake (Pepe and McLennan 2002), whereas myocardial 
oxygen consumption was reduced by either fish oil feeding or ruthenium red, but not by 
ryanodine (Pepe and McLennan 2002).  Ventricular myocytes from fish oil fed rats also have 
 31
lower mitochondrial [Ca2+] (Pepe et al. 1999).  There is a strong relationship between Ca2+ 
mechanisms in fatal arrhythmias underpinning acute ischaemic episodes in animals and in 
man (Pepe and McLennan 2002; Clusin 2003) and there appears to be a congruence between 
the antiarrhythmic actions of dietary omega-3 LC-PUFA in vivo and in vitro and effects on 
intracellular Ca2+ handling (Table 2).  This stands in contrast to the lack of correspondence 
between the acute and chronic effects of omega-3 LC-PUFA on Na+ channels (Table 1) or 
membrane fluidity in isolated myocytes (Table 2).  In contrast, many cellular Ca2+-related 
mechanisms are modulated by omega-3 LC-PUFA (Siddiqui et al. 2008) and accordingly, the 
one area of consistency between the acute and chronic (membrane incorporation) effects of 
omega-3 LC-PUFA relates to cellular Ca2+ handling.   
4.3. INTRACELLULAR MESSENGERS 
4.3.1. Phosphoinositides 
Intracellular Ca2+ overload underpins cardiac arrhythmias of many different aetiologies, 
including those stimulated by myocardial ischaemia and reperfusion, digitalis glycosides and 
catecholamines (Clusin 2003).  Fish oil fatty acids inhibit arrhythmias stimulated by all of 
those conditions.  In addition to directly measured effects on Ca2+ handling described above, 
the dietary incorporation of omega-3 fatty acids into myocardial membranes reduces the 
release of inositol 1,4,5-trisphosphate (IP3) from (pig) cardiomyocytes in response to alpha-
adrenoceptor stimulation (Nair et al. 2000) and from rat hearts in response to ischaemia and 
reperfusion, simultaneously preventing the corresponding ventricular fibrillation (Anderson 
et al. 1996).  Depletion of intracellular Ca2+ stores inhibits both IP3 release and arrhythmias in 
isolated hearts or atria subjected to regional ischaemia or simulated ischaemia (Woodcock et 
al. 1996).  Conversely, Ca2+ overload stimulates IP3 release (Woodcock et al. 1996).  IP3, 
regarded as a Ca2+ releasing second messenger, is derived from the cell membrane by the 
action of phospholipase C on phosphatidyl inositol.  Receptor mediated phospholipase C 
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activity is inhibited in rat cardiomyocytes following incorporation of EPA into membrane 
phospholipid (DHA not tested) (deJonge et al. 1996a; deJonge et al. 1996b), which could 
occur as a consequence of altered phosphatidyl inositol fatty acid composition (Charnock et 
al. 1986) reducing its vulnerability to phospholipase action.  Thus, the omega-3 fatty acids 
appear to interact with cellular Ca2+ homeostasis at several levels, potentially allowing them 
to short-circuit an arrhythmogenic cycle where Ca2+ initiates IP3 release and IP3 stimulates 
Ca2+ release.  
4.3.2. Eicosanoids and other fatty acid derived bioactives 
Eicosanoids are a collective term for a series of bioactive compounds derived from 20 carbon 
PUFA, primarily omega-6 LC-PUFA arachidonic acid.  They include prostaglandins, 
thromboxanes, prostacyclins and the inflammatory mediator leukotrienes (Siddiqui et al. 
2008; Jenkins et al. 2009).  Modulation of eicosanoid metabolism is implicated in many 
actions of fish oil fatty acids because EPA can replace linoleic acid as substrate for 
cyclooxygenase and lipoxygenase enzymes, often leading to the production of less end 
product and biologically more benign end product (Lee et al. 1992; Siddiqui et al. 2008).  
Cyclooxygenase products derived from EPA are less arrhythmogenic in isolated myocytes 
than those derived from arachidonic acid (Li et al. 1997).  Furthermore, fish oil feeding has 
been found to reduce myocardial eicosanoid production in rat, guinea pig and marmoset 
monkey, with greater inhibition of the proarrhythmic TXA2 than of the antiarrhythmic 
prostacyclin PGI2 (Abeywardena et al. 1991a, b, c; Abeywardena and Charnock 1995; Oudot 
et al. 1995; Murphy et al. 1999).  This change in eicosanoid balance is demonstrable with 
high intakes of EPA (>4 g.d-1) (Fischer and Weber 1983, 1984) and provides a biologically 
plausible explanation for the increased bleeding tendency and antithrombotic actions of 
dietary fish oil (Dyerberg et al. 1978), particularly with the more favourable balance towards 
EPA in endothelium and platelets (Abeywardena et al. 1987; Lee et al. 1992) compared to 
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high DHA in myocardium.  In the heart, with little EPA incorporation, even the simple 
replacement of arachidonic acid by DHA might contribute to a less arrhythmogenic 
eicosanoid profile and contribute to the antiarrhythmic actions of fish oil, as seen in isolated 
cells during hypoxia (Oudot et al. 1995). 
 
In addition to the long recognised bioactive lipid mediator eicosanoids, the recent 
identification of an extended range of powerful lipid mediator resolvins and protectins 
derived directly from EPA and DHA via lypoxygenase and aspirin activated cyclooxygenase 
pathways (Serhan 2004; Weylandt et al. 2012) opens an array of prospective diet-derived 
effects on myocardial cell functioning responsive to selective incorporation of DHA. 
Resolvins are named for their principal role in the resolution of inflammation (Serhan 2004), 
and with inflammation a key component of ischaemia/ reperfusion, myocardial infarction and 
heart failure (Luo et al. 2009), there is prospect for identification of a role for these 
compounds in dietary omega-3 LC-PUFA physiological effects.  Early research shows that 
resolvin E1 (derived from EPA) can protect the heart against reperfusion injury, reducing 
infarct size (Keyes et al. 2010) as effectively as ischaemic preconditioning or fish oil feeding 
(Abdukeyum et al. 2008). No data are available regarding prevention of arrhythmias in this 
coronary occlusion model as arrhythmic animals were excluded from analysis of the infarct 
size.  Nor is there any data published about the DHA derived molecules, except for 
demonstration of the equal effectiveness of resolvin D1 with resolvin E1 in pain prevention 
and prevention of renal ischaemic damage.  
 
A recently identified, potent series of bioactive cytochrome P450 epoxy and hydroxy 
metabolites derived from the omega-6 LC-PUFA arachidonic acid are produced in the heart 
during ischaemia and reperfusion (Jenkins et al. 2009; Arnold et al. 2010; Konkel and 
Schunck 2011). The epoxyeicosatrienoic acids (EET) and 20-hydroxyeicosatetraenoic acid 
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(20-HETE) have a range of often opposing effects in the heart, where EET regulate 
sarcolemma L-type Ca2+ channels and ATP sensitive K+ (KATP) channels in mitochondria, 
myocardial sarcolemma and vascular smooth muscle. The mitochondrial KATP channels 
modulate reactive oxygen species generation and intracellular protective signalling.  In the 
sarcolemma, opening KATP channels shortens the cardiac action potential, reducing 
intracellular Ca2+ overload, and is thought to be a crucial mediator of cardiac preconditioning 
and post-ischaemic cardiac protection (Baxter and Ferdinandy 2001).  Activation of vascular 
KATP channel leads to membrane hyperpolarisation, reduces Ca
2+ influx, and is a key 
determinant of vascular tone (Lu et al. 2006).  The KATP channels respond to the falling ratio 
of ATP:ADP in ischaemia. At the same time, ischaemia stimulates phospholipase A2 activity, 
which acts to cleave arachidonic acid, EPA or DHA from membrane phospholipid, making it 
available for metabolism by the cyclooxygenase, lipoxygenase and cytochrome P450 
pathways (Jenkins et al. 2009).  The omega-6 arachidonic acid derived epoxy EET 
compounds are cardioprotective in ischaemia and reperfusion, decreasing myocardial infarct 
size and improving functional recovery.  However, they are countered by the hydroxy 
arachidonic acid derivative 20-HETE, which has opposing and detrimental effects in 
ischaemic injury.  In the rat heart, fish oil feeding replaces a proportion of arachidonic acid 
with DHA (Slee et al. 2010; Konkel and Schunck 2011) and largely reduces the production of 
arachidonic acid derived cardiotoxic 20-HETE (Abeywardena and Charnock 1995; Konkel 
and Schunck 2011), replacing it with a sevenfold increase in DHA derived 22-
hydroxydocosahexaenoic acid (22-HDoHE) (Konkel and Schunck 2011).  There is little 
evidence of EPA-derived epoxy or hydroxy metabolites in the heart even after fish oil 
feeding, in line with its low presence on the membrane phospholipids. The arachidonic acid 
derived metabolites have a range of opposing effects on inflammation and ischaemic organ 
and cell injury, and it has been established that substantial production of DHA epoxy and 
hydroxyl metabolites occurs in the heart after fish oil feeding (Arnold et al. 2010; Konkel and 
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Schunck 2011) However, aside from some evidence that the (potentially cardioprotective) 
epoxy derivatives of DHA have up to 1000 times the potency of arachidonic derived EET in 
activating vascular KATP channels to promote dilation of coronary microvessels (Lu et al. 
2002), their cellular effects are, like the resolvins, largely unexplored.  With more than 20 
different bioactives derived from EPA and DHA there is a strong prospect for their 
involvement in omega-3 LC-PUFA action and the KATP channel with its role in ischaemic 
protection, and preventing Ca2+ overload may be a prime target.   
5. MYOCARDIAL ENERGETICS OF ARRHYTHMIA AND HEART FAILURE 
In addition to direct interaction with arrhythmic mechanisms affecting cellular 
electrophysiology, dietary fish oil increases myocardial oxygen efficiency in the isolated 
heart through reducing oxygen demand without reducing cardiac output or external work.  
This occurs independently of heart rate and provides the heart with enhanced coronary 
vasodilator reserve (Pepe and McLennan 2002).  Vasodilator reserve is the term given to the 
reserve capacity to dilate coronary arteries to provide increased flow on demand.  It is 
commonly low in conditions of cardiac hypertrophy and heart failure (McLennan et al. 2012), 
providing limits to exercise capacity without creating ischaemia. In the early reperfusion of 
ischaemic myocardium (e.g. saved infarct) it is common for contractile function and cardiac 
output to be depressed (myocardial stunning).  This puts the post-ischaemic heart at risk of 
high sympathetic stimulation to compensate the declining cardiac output through increased 
heart rate.  Dietary fish oil enhances early post-ischaemic myocardial recovery in animals 
(Demaison et al. 1994; al Makdessi et al. 1995; Pepe and McLennan 2002, 2007; Abdukeyum 
et al. 2008).  Ischaemia and reperfusion is a powerful stimulus for myocardial Ca
2+ overload 
(Piper 2000), leading to: increased diastolic Ca2+, retarding relaxation; and increased 
sarcoplasmic reticulum Ca2+, promoting Ca2+ sparks and arrhythmia. Usually a passive 
bystander in Ca2+ homeostasis, the mitochondria acutely become overloaded as well, resulting 
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in over-activation of Ca2+- dependent energy consuming enzymatic reactions and generation 
of reactive oxygen species (Peng and Jou 2010).  The oxygen sparing cardioprotective action 
of fish oil may be indirectly mediated through reduced intra-mitochondrial Ca2+ altering 
mitochondrial function (Pepe et al. 1999). It provides a form of nutritional preconditioning 
that protects against acute ischaemic insult (Abdukeyum et al. 2008), improves post-
infarction survival (Zaloga et al. 2006), and promotes work capacity in the hypertrophied and 
failing heart (McLennan et al. 2012).  Ischaemia produces energy wasting metabolic 
responses stimulated by mitochondrial Ca2+ overload (Demaison et al. 1996; Peng and Jou 
2010) but fish oil feeding improves post-ischaemic recovery of mitochondrial energy 
metabolism (Demaison et al. 1994) and reduces futile cycling of reactions consuming oxygen 
(Grynberg and Demaison 1996). Inhibition of mitochondrial Ca2+-uptake abolishes the 
dietary-induced differences in cardiac oxygen consumption (Pepe and McLennan 2002).  By 
reducing myocardial oxygen demand, the omega-3 LC-PUFA increase the reserve coronary 
perfusion capacity (Pepe and McLennan 2002) and the reserve work capacity of the normal 
(Abdukeyum et al. 2008) or hypertrophied heart (McLennan et al. 2012), raising the threshold 
of work that the heart can perform before demand creates ischaemic conditions to stimulate 
changes in intracellular Ca2+ that may be arrhythmogenic or conducive to failure. 
6. CONCLUSIONS 
The mammalian myocardium has in common with other excitable tissue, a preference to 
accumulate the omega-3 LC-PUFA, DHA and it avidly incorporates high concentrations 
when they are provided in the diet.  Fish oil feeding studies mainly demonstrate physiological 
effects of increasing DHA in cardiac membranes.  Accordingly, DHA is the active 
component of fish oil in preventing cardiac arrhythmia, lowering heart rate and 
preconditioning the heart to resist a variety of insults – all are intrinsic effects dependent 
upon changing the fatty acid composition of the heart. The lowering of triacylglycerols and 
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blood pressure to influence plaque formation and ischaemic heart disease are extrinsic to the 
fatty acid composition of the myocardium.  Selective antiarrhythmic effects are demonstrable 
for DHA over EPA when provided as purified fatty acids in the diet of rats (McLennan et al. 
1996), and heart rate in healthy humans is selectively lowered by DHA (Grimsgaard et al. 
1998).  Taken in conjunction with the observation that EPA and DHA are often equivalent in 
their cellular actions in isolated myocyte systems (Table 1, Table 2), the selectivity for DHA 
in dietary interventions likely resides partly in its preferential availability within the cell by 
virtue of its selective incorporation into excitable cell membranes (McLennan and 
Abeywardena 2005; Arnold et al. 2010). The appearance of antiarrhythmic effects with 
dietary fish oil feeding coincides in time with DHA incorporation into cell membranes 
(McLennan 2001; Owen et al. 2004).  Critically, the sometime failure of fish oil supplement 
clinical trials to replicate epidemiological findings may reflect the all too frequent use of 
supplements rich in EPA and low in DHA, that stands in contrast to the predominant 
provision of DHA in populations that regularly consume fish.  
 
Whilst international guidelines for fish oil consumption focus on treatment of heart disease, 
they also make recommendations for cardiovascular health and disease prevention, most 
commonly ~500 mg.d-1 of EPA+DHA for healthy adults (Vannice and Rasmussen 2014).  
The recommended dietary intakes represent a compromise between the high doses required 
for triacylglycerol lowering (and for which there is strong randomised control trial evidence) 
and the lower intakes associated with cardiovascular health in population studies.  With a 
clear delineation of low and high dose effects attributable to intrinsic and extrinsic cardiac 
physiological roles of omega-3 LC-PUFA respectively (Figure 2), we can now be more 
certain about accepting the intakes derived from the population studies to optimise healthy 
heart performance as they are based on cardiac intrinsic effects of fish oil fatty acids.  These 
studies identify 250 mg.d-1 EPA+DHA for maximal slowing the heart rate (Mozaffarian et al. 
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2005c) and reducing risk of sudden death or heart failure (Mozaffarian and Rimm 2006). 
Considering 100 g of salmon contains approximately 2000 mg EPA+DHA, then 200 g of 
salmon per week should be plenty.  The major consideration before taking supplements is: do 
you get enough from your diet?  Historically, the western diet has become poor in omega-3 
PUFA (Leaf and Weber 1988), which is also revealed by the low median intake of 
EPA+DHA in the modern Australian diet (estimated at 24-60 mg.d-1) (Meyer et al. 2003; 
Howe et al. 2006), perhaps to the point of deficiency (Flock et al. 2013a) and put further at 
risk as nutritional intake declines with age. There is little evidence to suggest going beyond 
the 250 mg.d-1 EPA+DHA will provide any physiological benefit for a fit and healthy 
individual, but they might consider opting for a supplement with more DHA than EPA if they 
are not eating fish. 
 
Whilst a large body of research has clearly and unequivocally identified acute inhibition of 
myocardial Na+ currents as a primary target for omega-3 LC-PUFA antiarrhythmic action and 
heart rate slowing in isolated cell systems (Leaf et al. 2005; Kang 2012), these effects are 
shared indiscriminately by other PUFA as well as local anaesthetics and alcohol. In other 
words, they may be attributable to a non-specific detergent-like or membrane stabilisation 
that is not representative of dietary mediated membrane DHA incorporation.   On the other 
hand, the omega-3 LC-PUFA have cellular electrophysiological effects on Ca2+ handling that 
demonstrate resistance to stimuli that induce cellular Ca2+ overload and uncoordinated 
cytosolic Ca2+ fluctuations (Leaf et al. 2005; Kang 2012).  The changes in Ca2+ handling are 
not shared by the omega-6 fatty acids in vitro and are equally demonstrable in cells harvested 
from fish oil fed animals.  Modulation of Ca2+ handling can in turn, directly or indirectly 
underpin: arrhythmia prevention; heart rate slowing; improved contractile function and 
relaxation; decreased myocardial oxygen consumption; and resistance to ischaemic injury.  
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Much of the clinical and epidemiological and animal dietary evidence converges to strongly 
support a role for arrhythmia prevention and heart rate lowering by fish oil omega-3 fatty 
acids in reducing heart disease mortality risk. The antiarrhythmic effects and other direct 
effects on heart function occur at lower doses and are independent of and additional to any 
beneficial effect on the classical risk factors of plasma triacylglycerols and hypertension.  
Incorporation of DHA into myocardial membranes is demonstrable with very low 
supplemental intakes and evidence suggests the effects of consuming fish represent 
correction of a dietary deficiency rather than a therapeutic effect, supporting a move towards 
establishing a recommended daily intake for DHA (Flock et al. 2013a).  While the range of 
electrophysiological effects coupled with influences on intracellular second messengers and 
lower myocardial oxygen demand indicate several potential mechanisms of action and it is 
likely that no single mechanism is unique in providing antiarrhythmic protection, cellular 
Ca2+ homeostasis appears to be the key to a number of the potential mechanisms.  These 
include electrophysiological and metabolic effects that can be demonstrated both in isolated 
cells and in the whole heart and could link to second messenger effects and intracellular 
signalling (Siddiqui et al. 2000; Jenkins et al. 2009).  The evidence suggests that 
antiarrhythmic protection, heart rate slowing and optimised cardiac contractile function are 
best achieved through regular consumption of fish oor fish oil to promote incorporation of 
DHA into membrane lipids, however many of the effects observed in vitro await validation in 
dietary modulated cells known to have omega-3 derived arrhythmia protection in vivo.  
 
This review identifies the pleiotropic physiological effects of fish oil as either intrinsic – 
direct effects on heart function dependent upon membrane incorporation, or extrinsic – 
indirect effects through triacylglycerols, blood pressure and atherosclerosis. Of the significant 
omega-3 fatty acids, DHA predominates over EPA in fish we eat and is preferentially 
incorporated into myocardium. Extrinsic effects are achieved only with doses of EPA+DHA 
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exceeding 3 g.d-1, whereas intrinsic effects are derived from usual dietary intakes of less than 
1 g.d-1, perhaps as little as 250 mg.d-1, and include improved efficiency of myocardial oxygen 
use, contractility, resting heart rate, and nutritional preconditioning of the heart to resist 
ischaemic injury, heart failure and arrhythmias.  DHA is selectively active over EPA in heart 
rate slowing and arrhythmia prevention.  Intrinsic modulation of cellular Ca2+ handling 
provides a biologically plausible physiological basis for both healthy heart function, and 
nutritional prevention of sudden death, and heart failure. It is worth noting for future 
investigation, that fish oil nutritional preconditioning of the heart has more than a passing 
similarity to the sustained cardioprotective effects of exercise training.  
 
The disparate intakes and physiological mechanisms underpinning different clinical 
endpoints and selectivity for DHA, plus the common employment of high EPA, low DHA 
oils for clinical trials can perhaps explain the sometimes contradictory outcomes of fish oil 
clinical trials and provide insight to nutritional optimisation of cardiac function and selection 
criteria for clinical trials based on an improved hypothesis regarding mechanism of action. 
 
Future basic research, still needed to characterise plausible mechanisms of action of omega-3 
LC-PUFA, should concentrate on the fatty acid concentrations and dietary intakes shown to 
be effective by observational population studies, in order to separate the nutritional from the 
therapeutic effects.  What has been established is that only small additional intkes are 
required to induce physiological change. The electrophysiological effects observed with acute 
administration of fatty acids in cellular systems, must be reproducible in cells having dietary 
derived membrane compositional change.  Most importantly, individual fatty acid evaluations 
should always include DHA, as it is the principal fatty acid incorporated into myocardial 
membrane phospholipid.  The recent discovery of DHA-derived cyclooxygenase, 
lipoxygenase and cytochrome P450 products promises to be a fruitful area of research.  “A 
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new link between omega-3 fatty acids and cardiac disease” (Westphal et al. 2011) describes 
the pathways and some effects of the cytochrome P450 epoxy and hydroxy docosanoids 
derived from DHA.  This may explain the many parallels that the physiological effects of 
dietary fish oil and myocardial membrane DHA share with attenuation of Ca2+ overload. 
Future applied research should focus on experimental or disease models (patient populations) 
that demonstrate a pathophysiological basis that is relevant to biologically plausible intrinsic 
mechanisms of action for fish oil fatty acids, avoiding the indiscriminate pooling of 
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Figure 1.  
 
Figure 1. 
Schematic pathway of polyunsaturated fatty acids (PUFA) conversion through chain 
elongation/desaturation, illustrating the main rate-limiting competition point (-6 desaturase). 
Omega-6 PUFA pathway in black with solid line; Omega-3 PUFA pathway in grey with 
dashed line; Principal dietary sources in bold.  Principle myocardial membrane PUFA boxed;  
Fatty acid nomenclature: e.g. 22:6 n-3 - indicates carbon chain length (22): number of double 
bonds (6) and position of 1st double bond from terminal methyl end of the molecule (n-3). 
LA linoleic acid 18:2 n-6; ALA alpha-linolenic acid 18:3 n-3; AA arachidonic acid 20:4 n-6; EPA 
eicosapentaenoic acid 20:5 n-3; DPA docosapentaenoic acid; DHA docosahexaenoic acid 




Figure 2.  
 
 
Linking omega-3 fatty acid requirements for physiological and clinical endpoints with 
intrinsic cardiac and extrinsic extra-cardiac mechanisms.  










Figure 3. Relationship between the ratio of polyunsaturated to saturated fats (P:S ratio) in rat 
diets to the arrhythmia score measured during myocardial ischaemia in vivo or in vitro.   
sheep fat,  palm oil,  olive oil,  reference (rat chow),  canola oil,  soybean oil,  
sunflower seed oil,  fish oils.  Symbols represent mean P:S ratio for the supplemented diet 
and mean arrhythmia score.  Vertical bars represent SEM for arrhythmia score. Horizontal 
bars represent SEM for P:S ratio of diets. r2 correlation coefficient calculated from all data 
excluding fish oil diets. Solid line represents regression line of best fit, dotted lines represent 
the 95% confidence intervals. P < 0.0001 for slope.  Figure adapted from (Grynberg et al. 
1997) with data from (McLennan et al. 1985, 1988, 1989a; McLennan et al. 1989b; 
McLennan et al. 1990; Charnock et al. 1991; McLennan 1993; Siebert et al. 1993; McLennan 
and Dallimore 1995; Abdukeyum et al. 2008)  
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Table 1.  Summary of influence of fatty acids on isolated cell ionic currents 
 INa+ ITO Inward 
rectifier IK+ 
If L-type ICa2+ 
 amplitude , 
inactivation  
inhibited  amplitude , 
inactivation  
 density amplitude  
      
Acute fatty acid presentation 

















Chronic fatty acid presentation 
Effective  No diet 
tested 


















 decrease;  increase; All acute presentations administered into extracellular incubate; EPA 
eicosapentaenoic acid 20:5 n-3; DHA docosahexaenoic acid 22:6 n-3; ALA alpha-linolenic 
acid 18:3 n-3; AA arachidonic acid 20:4 n-6; LA linoleic acid 18:2 n-6; ETYA eicosatetraynoic acid 
non-metabolisable AA analogue; OA oleic acid 18:1n-9; SFA saturated fatty acid;  INa+ Na
+ current; 

























Acute fatty acid presentation 

















OA no effect; 
Luminal - no 
other tested 
LA, OA, SFA 
no effect 
Chronic fatty acid presentation 









None tested  















 decrease; All acute presentations administered into extracellular incubate unless otherwise 
stated;. EPA eicosapentaenoic acid 20:5 n-3; DHA docosahexaenoic acid 22:6 n-3; ALA 
alpha-linolenic acid 18:3 n-3; AA arachidonic acid 20:4 n-6; LA linoleic acid 18:2 n-6; ETYA 
eicosatetraynoic acid non-metabolisable AA analogue; OA oleic acid 18:1n-9; SFA saturated fatty 
acid;  
 
